Viela Bio's inebilizumab for NMOSD and Genfit's elafibranor for PBC win breakthrough designations; Novartis uses priority review voucher for wet AMD treatment brolucizumab.
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
